Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

European Journal of Clinical Pharmacology

Volumn 52, Issue 2, 1997, Pages 129-133

  Spigset, O ^a   Granberg, K ^a   Hagg S ^a   Norstrom A ^a   Dahlqvist, R ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYP2D6; Cytochrome P 450; Fluvoxamine; pharmacokinetics; phenotyping

Indexed keywords

CYTOCHROME P450; DEXTROMETHORPHAN; FLUVOXAMINE; FLUVOXAMINE MALEATE; ISOENZYME; MEPHENYTOIN; SEROTONIN UPTAKE INHIBITOR; TUSSIDYL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME POLYMORPHISM; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0030957166     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050261     Document Type: Article

References (24)

1. Wilde MI, Plosker GL, Benfield P (1993) Fluvoxamine. Drugs 46: 895-924
2. Palmer KH, Benfield P (1994) Fluvoxamine. CNS Drugs 1: 57 87
3. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R (1995) Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 58: 399-403
4. Dahl M-L, Bertilsson L (1993) Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3: 61-70
5. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussman BD (1992) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51: 278-287
6. Skjelbo E, Brøsen K, Hallas J, Gram LF (1991) The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 49: 18-23
7. Kramer Nielsen K, Brøsen K, Hansen MG, Gram LF (1994) Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 55: 518 527
8. Sindrup SH, Brosen K, Hansen MGJ, Aaes-Jørgensen T, Overø KF, Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15: 11-17
9. Baumann P, Jonzier-Perey M (1988) GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin. Clin Chim Acta 171: 211-222
10. Hou Z-Y, Pickle LW, Meyer PS, Woosley RL (1991) Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 49: 410-419
11. Schmid B, Bircher J, Preisig R, Küpfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 38: 618-624
12. Tybring G, Bertilsson L (1992) A methodological investigation on the estimation of the S-mephenytion hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 2: 241-243
13. Sanz EJ, Villén T, Alm C, Bertilsson L (1989) S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clin Pharmacol Ther 45: 495-199
14. van Harten J, Lönnebo A, Grannén A (1994) Pharmacokinetics of fluvoxamine after intravenous and oral administration (abstract). Neuropsychopharmacology 10: 104S
15. Alvan G, Piafsky K, Lind M, von Bahr C (1977) Effect of pentobarbital on the disposition of alprenolol. Clin Pharmacol Ther 22: 316-321
16. Rowland M, Tozer TN (1989) Clinical pharmacokinetics: concepts and applications, 2nd edn. Lea & Febiger, Philadelphia, pp 180-182
17. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P (1995) Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 31: 347-353
18. Overmars H, Scherpenisse PM, Post LC (1983) Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet 8: 269-280
19. de Vries MH, Raghoebar M, Mathlener IS, van Harten J (1992) Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 14: 493-498
20. van Harten J, van Bemmel P, Dobrinska MR, Ferguson RK, Raghoebar M (1991) Bioavailability of fluvoxamine given with and without food. Biopharm Drug Dispos 12: 571-576
21. Bertilsson L, Åberg-Wistedt A, Gustafsson LL, Nordin C (1985) Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7: 778-780
22. Spigset O, Öhman R (1996) Case of fluvoxamine intoxication demonstrating non-linear elimination pharmacokinetics. J Clin Psychopharmacol 16: 255-256
23. Crewe HK, Lemmard MS, Tucker GT, Woods FR, Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34: 262-265
24. Skjelbo E, Brøsen K (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34: 256-261